Future Trials Conference: Decentralized, Direct-to-Patient & Virtual Clinical Trials
Virtual Event: 8:30 am ET
22nd June 2021
Future Trials Conference: Decentralized, Direct-to-Patient & Virtual Clinical Trials
Our online conference will explore the challenges in decentralised and remote clinical trials, both in the face of COVID-19 and in the long term, post-pandemic. Divided into two streams looking at Early Virtual Trial Maturity and Advanced Virtual Trial Maturity respectively, this one day conference will feature a number of case studies, panel discussions and interactive sessions focused on making your trial run as smoothly as possible.
With over 40 solution providers the conference will be a perfect platform to reconnect with current business partners, meet new vendors and discover which new technologies are being employed to improve your decentralised clinical trials.
At each virtual conference we create a welcoming networking environment and an educational program packed with the latest case studies, techniques and providers to set your trial apart. The Arena team will bring some of the leading voices in decentralised trials who are best situated to answer your questions and provide you the insight you need to successfully run your trial.
Register now to join our 2021 online conference in June.
A FANTASTIC NETWORK OF YOUR PEERS AND COLLEAGUES RIGHT AT A TAP OR CLICK OF A BUTTON
Simply register, login on the day and get ready to connect and learn. With the right network at your fingertips, catching up with your peers has never been so easy – even from a distance.
TESTIMONIALS
-
‘That was a superb day, it feels like we’ve been at a real, in person, conference!’ Worldwide Clinical Trials
-
‘A great event, I met more people than I do at an in-person event and I’ve got loads of follow ups’ Conversis
-
‘The whole setting is actually very well accomplished! Thanks again for the invitation!’ Apogenix AG

Jennifer McNary
Patient Advocate,
Biography:
Session Details: OPENING KEYNOTE PRESENTATION: Decentralized clinical trials: a patient perspective 22-06-2021, 8:30 am View In Agenda

Anne Marie Mercurio
Patient Advocate,
Biography:
Session Details: ROUNDTABLE: No excuses. Decentralize trials for patient benefits. 22-06-2021, 10:45 am View In Agenda

Aman Thukral
Head of Digital Operations and eCOA,AbbVie
Biography:
Session Details: PLENARY PANEL DISCUSSION: Moving on from COVID-19: preparing for decentralized trials in the future 22-06-2021, 9:30 am View In Agenda

Prasun J Mishra
Founder CEO,Agility Pharmaceuticals
Biography: Dr. Mishra (Ex-Genentech, Ex-NCI, Ex-NIH) is the Founder and CEO of Agility Pharmaceuticals. He is a serial entrepreneur who founded his first company after graduating high school, and second company during his PhD. Since then, he has accumulated a wealth of experienced by building, investing and advising numerous other companies. He is an investor/ co-founder/ board member of a few US based corporations focused on accelerating drug discovery & development, blockchain & digital health. Dr. Mishra is also founding president & CEO of American Association for Precision Medicine (AAPM) and is leading research efforts focused on preventing & curing chronic diseases; not only treating the sick but also providing knowledge/tools to individuals to live longer, healthier lives. Widely recognized as a thought leader in the field of Technology and Healthcare, Dr. Mishra has keynoted, chaired, curated and organized numerous successful international conferences. Prior to Agility Pharma, Dr. Mishra served as a scientist and Principal Investigator at Genentech, Roche. Moreover, his passion for drug development and precision medicine has led to identification of new drug targets, biomarkers, companion diagnostics and several drugs/ combinations in the clinic. His research work has been recognized globally by over 40 prestigious awards and honors. Due to his unique perspective & selfless service, he is highly respected & sought-after mentor to many. The companies that he has advised have raised multimillion dollars. Notably, he serves as a mentor and advisor to startup accelerators such as IndieBio, Health2.0’s Project Zygote and CLSI FAST program, to help grow California’s life sciences innovation ecosystem.
Session Details: PLENARY PANEL DISCUSSION: Considerations and best practice in direct-to-patient distribution models 22-06-2021, 3:00 pm View In Agenda

Jessica Mega
Chief Medical & Scientific Officer,Baseline by Verily
Biography:
Session Details: Delivering on the promise of patient-centric decentralized trials 22-06-2021, 9:00 am View In Agenda

Ahmad Namvargolian
Chief Executive Officer,Care Access
Biography: Ahmad Namvargolian co-founded Care Access in 2015 which quickly grew into one of the most trusted clinical research companies in the US. Namvargolian’s one core mission for Care Access is to remove barriers in clinical research for sponsors, physicians, and patients; making clinical research accessible to all. This mission was put to test in 2020 when COVID-19 swept through the world causing shutdowns of businesses and clinics. Under Namvargolian’s leadership, Care Access expanded its unique industry solutions and delivered on the largest and most complex decentralized trial to date, taking clinical research directly to patients by deploying “Jump Teams” anywhere in the country and creating pop-up research infrastructure on demand. Having established over 150 “pop-up” sites, Care Access has enrolled over 4,000 patients and conducted over 60,000 home visits. Prior to Care Access, Namvargolian was a research scientist and earned his Master’s Degree in Public Policy from University of Chicago and Bachelor of Science degree in Bioengineering and Material Science from UC Berkeley.
Session Details: PLENARY PANEL DISCUSSION: Moving on from COVID-19: preparing for decentralized trials in the future 22-06-2021, 9:30 am PLENARY PANEL DISCUSSION: Considerations and best practice in direct-to-patient distribution models 22-06-2021, 3:00 pm View In Agenda

Anka Ehrhardt
Science Director, Clinical Research,CHDI Foundation
Biography:
Session Details: PLENARY PANEL DISCUSSION: Moving on from COVID-19: preparing for decentralized trials in the future 22-06-2021, 9:30 am Is this biomarker ready for a trial? 22-06-2021, 1:30 pm View In Agenda

Stephanie Kallay
Director, Patient Advocacy and Outreach,Crinetics Pharmaceuticals
Biography:
Session Details: PLENARY PANEL DISCUSSION: Moving on from COVID-19: preparing for decentralized trials in the future 22-06-2021, 9:30 am View In Agenda

Rebecca Kush Ph.D.
Chief Scientific Officer,Elligo Health Research
Biography:
Session Details: Leveraging EHRs and community practices to accelerate patient-focused decentralized clinical trials 22-06-2021, 10:15 am View In Agenda

Melaina Boyce
Director, Clinical Innovation,EMD Serono the Healthcare business of Merck KGaA, Darmstadt, Germany
Biography:
Session Details: PLENARY PANEL DISCUSSION: Moving on from COVID-19: preparing for decentralized trials in the future 22-06-2021, 9:30 am View In Agenda

Vincent Puglia
Sr. Director, Strategic Alliances ,Endpoint
Biography: Vincent is a life-long operations and business management professional with a 24-year career across construction, environmental science, technology and pharmaceuticals. Vincent provides leadership at the nexus of building relationships, innovating technology and driving collaborative efforts to design, build and grow systems of all types and complexity in the real and digital in the service of patients and clinical trials.
Session Details: Leveraging partnered ecosystems: a practical discussion on how to interface systems and processes 22-06-2021, 4:45 pm View In Agenda

Bonnie Bain, PhD
Global Head and Executive Vice President of Healthcare Operations and Strategy,GlobalData Healthcare
Biography: Bonnie Bain, PhD, is the Global Head and EVP of Healthcare Operations and Strategy. Bonnie has over 20 years’ experience in the healthcare sector and a proven track record of developing innovative solutions on both the client and agency sides of the business. Bonnie was GlobalData Healthcare’s first Western analyst, and under her leadership, the company launched a number of premium syndicated reports, analytical tools, and databases in the pharmaceuticals and medical devices space. Prior to GlobalData, Bonnie was Vice President and Global Research & Analysis Director for Informa’s Pharma Division, which includes Datamonitor Healthcare, Scrip Group, and Business Insight. Bonnie also worked for several years at Decision Resources as an Analyst and Project Manager. On the client side of the industry, Bonnie worked for several years as a Senior Manager in Marketing Strategy and Analytics at Boston Scientific, where her work contributed to the successful commercialization of the first ever Access and Visualization Platform at the company. Bonnie has a PhD in Biochemistry and Molecular Biology from Purdue University and completed a Post-Doctoral Fellowship in Molecular Pharmacology at the University Of Miami School Of Medicine. She also has a graduate certificate in Applied Management Principles from Purdue University Krannert School of Management.
Session Details: Chair’s opening remarks 22-06-2021, 8:25 am View In Agenda

Catherynne Cruz-Sheckner
Director Clinical Supplies, Ionis Pharma,
Biography:
Session Details: PLENARY PANEL DISCUSSION: Considerations and best practice in direct-to-patient distribution models 22-06-2021, 3:00 pm View In Agenda

Greg Tuyteleers
Global Operations Head, Managed Access, Global Lead Trial Virtualization,Janssen R&D
Biography:
Session Details: PLENARY PANEL DISCUSSION: Moving on from COVID-19: preparing for decentralized trials in the future 22-06-2021, 9:30 am View In Agenda

Aswin Chandrakantan
MD, Chief Medical Officer and Head of Life Sciences,Komodo Health
Biography:
Session Details: Using real-world evidence to accelerate protocol design, site selection, feasibility, and patient recruitment 22-06-2021, 11:45 am View In Agenda

Mads Bo Christensen
Research and Development Project Manager,Leo Pharma
Biography:
Session Details: CASE STUDY: Revolutionising decentralised trials at Leo Pharma 22-06-2021, 12:15 pm View In Agenda

Thomas Coquelle
Principal Clinical Project Manager,Leo Pharma
Biography:
Session Details: CASE STUDY: Revolutionising decentralised trials at Leo Pharma 22-06-2021, 12:15 pm View In Agenda

Amanda Nite
Director, Product Management,Medidata, a Dassault Systemes Company
Biography: Amanda is currently Director, Product Management at Medidata, a Dassault Systemes Company and is responsible for developing and implementing the strategic direction for the Rave RTSM Product. She has been in the Life Science Industry for more than 20 years and has held multiple roles in the eClinical space as well as pharmaceutical development and manufacturing. Before joining Medidata two years ago, Amanda focused on patient centricity and reducing patient burden as the Sr. Director of Operations at Altavoz, an eCOA startup that was acquired by IQVIA. Prior to that, Amanda was Sr. Director, RTSM at Bioclinica and oversaw RTSM Operations. Amanda is also active in the Healthcare Businesswomen's Association and is the Monitoring and Evaluation Lead for Women in Healthcare Give Back.
Session Details: PLENARY PANEL DISCUSSION: Considerations and best practice in direct-to-patient distribution models 22-06-2021, 3:00 pm View In Agenda

Alicia Staley
Senior Director, Patient Engagement,Medidata, a Dassault Systèmes Company
Biography: Alicia has over 20 years of experience in software design and information systems management. She has a Mechanical Engineering Degree from Syracuse University and from Boston University with a Masters of Information Systems and an MBA. At Medidata, Alicia works to infuse the patient perspective throughout the product development lifecycle and help engage patients in novel ways. Alicia is also a three-time cancer survivor, first diagnosed with Hodgkin’s disease as a sophomore during college. Over the past 10 years, she's applied her engineering background to improve the patient experience for those dealing with cancer. With an extensive network of patient advocates and non-profit organizations, she collaborates with a wide range of stakeholders to help improve processes and policies that impacts cancer care. An early adopter of social media, she co-founded #BCSM, which attracts over 1,000 global participants each week to its scheduled online discussions. Since its launch, #BCSM has been showcased at SXSW in 2013, 2014, 2015, and 2017 and is recognized as the gold standard for disease-specific social media networks. She’s co-led numerous research studies on how patients share information in online forums As a champion of patient advocacy and engagement, she understands the critical issues facing patients seeking to engage in clinical research. With a keen focus on improving access to clinical trials, Alicia is passionate about making a difference for patients seeking clinical trials.
Session Details: ROUNDTABLE: No excuses. Decentralize trials for patient benefits. 22-06-2021, 10:45 am View In Agenda

Marc Kaufman
Director, Product Management, RTSM Customer Adoption and Value Realization,Medidata
Biography:
Session Details: ROUNDTABLE: No excuses. Decentralize trials for patient benefits. 22-06-2021, 10:45 am View In Agenda

Jeremy R. Price
Director, Clinical Innovation & Strategic Partnerships,Pfizer
Biography:
Session Details: PLENARY PANEL DISCUSSION: Moving on from COVID-19: preparing for decentralized trials in the future 22-06-2021, 9:30 am View In Agenda

Laurie Berry
Development Scientist,Pfizer
Biography: Laurie Berry, Ph D, PMP is Director, Clinical Innovation & Strategic Partnerships, in Pfizer’s Global Product Development Operations Center of Excellence. She is responsible for leading Pfizer’s Direct to Patient Initiative as part of the Pfizer’s Decentralized Clinical Trials Community of Practice and finding new innovative ways to improve clinical studies. In previous roles, Laurie led Clinical study teams and BLA submissions for Global Product Development and Research & Development. Prior to this role, Laurie was a Clinical Supply Chain Led for 10 years. Prior to joining Pfizer in 1994, earned a BA/BS from St. Anslem College, and a PHD from the University of Vermont in Analytical Chemistry. When not at work, you may find me driving his two kids to their activities, walking, kayaking, boating and enjoying the beach.
Session Details: PLENARY PANEL DISCUSSION: Considerations and best practice in direct-to-patient distribution models 22-06-2021, 3:00 pm View In Agenda

Robin Sutherland
Vice President, Human Resources and Clinical Operations,Renovia
Biography:
Session Details: CASE STUDY: Lessons learned from switching to decentralised models in the middle of the COVID-19 pandemic 22-06-2021, 11:15 am View In Agenda

Sotirios Perdikeas
Global Head Resource Management & Analytics, Strategy, Portfolio & Clinical Operations,Roche

Emil Hoeck
Senior Director, Virtual Trial Solutions,Signant Health
Biography:
Session Details: Reduce site burden with virtual site monitoring: results from top 20 pharma pilot programs 22-06-2021, 11:45 am View In Agenda

Jessica Marer
Manager, Smart Planning, GCO,Teva Pharmaceuticals
Biography:
Session Details: CASE STUDY: Designing a decentralized trial for non COVID reasons: best practice and learnings for the future 22-06-2021, 11:15 am View In Agenda

Michal Gueron
Associate Director, Clinical Trials Planning and Operational Processes,Teva Pharmaceuticals
Biography:
Session Details: CASE STUDY: Designing a decentralized trial for non COVID reasons: best practice and learnings for the future 22-06-2021, 11:15 am View In Agenda

John Reites
CEO, THREAD,
Biography: Executive intrapreneur turned digital health entrepreneur, my career includes nearly 20 years leading global drug development, clinical research, and decentralized clinical trials (DCTs) for life science organizations. As CEO of THREAD, I lead our global organization in achieving our 1/5/30 mission to modernize clinical research by offering biopharma and CRO customers one (1) comprehensive platform that is five (5) times more inclusive and makes research 30% more efficient. After co-founding and growing THREAD, we were acquired in 2019 by JLL Partners and Water Street with strategic investment for continued growth and focus on accelerating drug development for our customers. Named one of the Top 100 Influencers in Digital Health, I also provide expertise and execution experience in digital health, clinical research innovation, and DCTs. Learn more about John at www.linkedin.com/in/johnreites
Session Details: Reduce costs and increase inclusion with DCTs 22-06-2021, 2:00 pm View In Agenda

David Larwood
CEO,Valley Fever Solutions
Biography: David Larwood is a founder, the CEO, and chief chemist for Valley Fever Solutions, running the manufacturing process for a novel antifungal headed for Phase 2a trials in 2022. In his role as BD lead, he is responsible for many aspects of the company’s planning and operations. Valley Fever Solutions is a small startup working first on a new and improved treatment for Valley Fever (coccidioidomycosis), for which NikZ will transform the standard of care. NikZ shows promise against other important fungal diseases. Mr. Larwood co-invented his first two commercial molecules before age 30. His PhD research at UC San Francisco established the foundation for PEGylated drugs widely used today. At UCSF he co-invented suitable PEGylated lipids to make the very first PEGylated liposomes. Earlier as a bench chemist, he was the first to make Iotrolan, a CT X-ray contrast agent, generic for decades, replaced in about 2005 by newer agents. Moving to law, in leading law firms he advised major companies on patent matters. After 3 years as a patent lawyer at Apple Computer, he took a VP role at startup FormFactor, staying in an IP role, then became the first General Counsel for startup Verisity Design, taking them public in 2001, then ultimately through successful acquisition in 2005. Mr. Larwood is the third of his family to be involved in Valley Fever. His father was a physician who developed an interest in the disease decades ago when the family moved to Bakersfield, California, a focal area for the disease. His mother started a foundation in 1998 and raised some $20M for research into vaccines against Valley Fever.
Session Details: PLENARY PANEL DISCUSSION: Considerations and best practice in direct-to-patient distribution models 22-06-2021, 3:00 pm View In Agenda

Michele Rhee
Vice President, Patient Affairs and Advocacy,X4 Pharma
Biography:
Session Details: PLENARY CASE STUDY: Running a decentralized trial for a rare disease study 22-06-2021, 4:15 pm View In Agenda

Suki Malhi
Senior Director, Clinical Affairs,Zogenix, Inc.
Biography:
Session Details: CASE STUDY: Direct-to-patient shipments in orphan drug trials and how to navigate hurdles to deliver drugs safely and efficiently 22-06-2021, 1:30 pm View In Agenda

Donald J. Kellerman
Vice President, Clinical Development and Medical Affairs,Zosano Pharma
Biography: Donald Kellerman is the Vice President of Clinical Development and Medical Affairs for Zosano Pharma. Dr. Kellerman has more than 30 years of experience working in several areas of the pharmaceutical industry, primarily clinical development. Dr. Kellerman has led registration trials in a number of therapeutic areas, including respiratory, allergy, ophthalmology, cardiovascular, and neurology. From 2008 to 2013, Dr. Kellerman served as Senior Vice President, Clinical Development and Medical Affairs at MAP Pharmaceuticals, Inc., where he led the development of Semprana for migraine. Prior to joining MAP, Dr. Kellerman held management positions at Inspire Pharmaceuticals, Inc. Glaxo Wellcome, plc, Sepracor, Inc., Ciba-GEIGY Corporation, and E.R. Squibb and Sons, Inc. He has served as project leader on multiple development teams including those working on Flovent,® Advair,® and Xopenex®. Dr. Kellerman received his Bachelor of Science and Doctor of Pharmacy from the College of Pharmacy at the University of Minnesota. He has authored major sections of eight NDAs, created labelling strategy for several pharmaceutical products, and has co-authored over 80 publications related to the results of clinical development activities.
Session Details: Assessing how clinical monitoring will change as a result of COVID-19 22-06-2021, 5:15 pm View In Agenda

A.K. Gupta
CTO,UBC

Rob Califf
Head of Clinical Policy and Strategy,Verily and Google Health
Biography:
Robert M. Califf, MD, MACC, is the Head of Clinical Policy and Strategy for Verily and Google Health. Prior to this Dr. Califf was the vice chancellor for health data science for the Duke University School of Medicine; director of Duke Forge, Duke’s center for health data science; and the Donald F. Fortin, MD, Professor of Cardiology. He served as Deputy Commissioner for Medical Products and Tobacco in the U.S. Food and Drug Administration (FDA) from 2015-2016, and as Commissioner of Food and Drugs from 2016-2017. A nationally and internationally recognized leader in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf is a graduate of Duke University School of Medicine. Dr. Califf was the founding director of the Duke Clinical Research Institute and is one of the most frequently cited authors in biomedical science.
Session Details: Delivering on the promise of patient-centric decentralized trials 22-06-2021, 9:00 am View In Agenda

Gordon Cummins MS
Vice President, Real-World Evidence,Science 37
Biography:
Session Details: Refining, rethinking, and decentralizing clinical research 22-06-2021, 3:45 pm View In Agenda

Alison Holland
Executive General Manager, Digital and Decentralized Solutions,Medable
Biography:
Session Details: Leveraging DCT solutions to increase the footprint of sites, improve patient access, and trial diversity 22-06-2021, 2:00 pm View In Agenda

EB McLindon
Senior Vice President Site, Patient and Decentralized Solutions,ICON
Biography: E.B. McLindon is an accomplished senior executive with proven ability to build, develop and manage businesses. Utilising a background in finance and technology, he helped create Accelovance, a CRO that owns and operates clinical research sites. E.B. is passionate about engaging patients – either directly through outreach or through site development, and simplify the research journey for both patients and sites.
Session Details: Engaging important stakeholders: patients and investigators 22-06-2021, 2:30 pm View In Agenda

Mary Costello
Head of Site and Investigator Network,Medable
Biography:
Session Details: Leveraging DCT solutions to increase the footprint of sites, improve patient access, and trial diversity 22-06-2021, 2:00 pm View In Agenda

Matty Culbreth-Notaro BSN, RN
Chief Operations Officer,ObvioHealth
Biography:
Session Details: The real world of DCTs: an insider perspective 22-06-2021, 12:15 pm View In Agenda

Pamela Tenaerts
Chief Scientific Officer,Medable
Biography:
Session Details: Leveraging DCT solutions to increase the footprint of sites, improve patient access, and trial diversity 22-06-2021, 2:00 pm View In Agenda

Susan Dallabrida PhD
Vice President of Clinical Science and Innovation,ObvioHealth
Biography:
Session Details: The real world of DCTs: an insider perspective 22-06-2021, 12:15 pm View In Agenda








ObvioHealth is a Virtual Research Organization (VRO) pioneering decentralized clinical research. We launched in 2017, leveraging tech innovation to tackle the inefficiencies in the clinical trial process by designing one of the first patient centric mobile apps and platform, making it possible for people to participate in trials from their homes.
Our technology and team of experienced clinical scientists, clinical operations experts, and visionary health technologists make clinical trials safer, easier, faster, and deliver better data. ObvioHealth is on a constant quest to improve our platform and the clinical trial experience to bring more life-improving innovations to market.













1nHealth Delivers Patient-Centric Online Recruitment.
We believe patient recruitment is about starting conversations. The most important elements: Who you talk to and What you say.
The future is almost certainly a personalized one, and that’s how we approach recruitment today. We exist to reach the right people, and present the study’s messaging that meets them where they are.
We deploy our patient-centric, inclusive targeting using engaging study assets that deliver high volumes of pre-qualified study participants, and it works…for Sponsors, and for Patients.
1nHealth. We Fill Studies.








Viedoc
Sponsorship opportunities
To enquire about sponsorship opportunities for the conference, please contact:
Alexander O’Leary
Portfolio Director
T: +44 207 947 2982
Speaker Opportunities
We identify and invite individuals we believe to be the best speakers in the market, if you think you can make a difference to the quality of our events please contact the programme director of the event:
Louisa Manning
Programme Director
ZOOM PHONE: +44 (0) 207 661 0906